Beyond Vascular Disruption: DMXAA (Vadimezan, AS-1404) as...
2025-10-18
This thought-leadership article explores the mechanistic and translational potential of DMXAA (Vadimezan, AS-1404) not only as a vascular disrupting agent but as a unique modulator of tumor endothelial biology and immune signaling. By synthesizing recent insights into the STING-JAK1 axis and integrating cutting-edge research, we provide strategic guidance for translational researchers on leveraging DMXAA for advanced cancer biology studies, highlighting its role in tumor vasculature normalization and antitumor immune activation.